Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Jerusalem G, Delea TE, Martin M, De Laurentiis M, Nusch A, Beck JT, Chan A, Im SA, Neven P, Lonshteyn A, Chandiwana D, Lanoue B, Fasching PA. Jerusalem G, et al. Among authors: lanoue b. Clin Breast Cancer. 2022 Jun;22(4):326-335. doi: 10.1016/j.clbc.2021.12.008. Epub 2021 Dec 20. Clin Breast Cancer. 2022. PMID: 35034858 Clinical Trial.
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Fasching PA, Beck JT, Chan A, De Laurentiis M, Esteva FJ, Jerusalem G, Neven P, Pivot X, Bianchi GV, Martin M, Chandiwana D, Lanoue B, Ridolfi A, Wang Y, Rodriguez Lorenc K, Nusch A. Fasching PA, et al. Among authors: lanoue b. Breast. 2020 Dec;54:148-154. doi: 10.1016/j.breast.2020.09.008. Epub 2020 Sep 23. Breast. 2020. PMID: 33065342 Free PMC article. Clinical Trial.
Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer.
Fasching PA, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, Lanoue B, Hu H, Thuerigen A, O'Shaughnessy J. Fasching PA, et al. Among authors: lanoue b. Cancer Manag Res. 2021 Nov 1;13:8179-8189. doi: 10.2147/CMAR.S325043. eCollection 2021. Cancer Manag Res. 2021. PMID: 34754238 Free PMC article.
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).
Harbeck N, Franke F, Villanueva-Vazquez R, Lu YS, Tripathy D, Chow L, Babu GK, Im YH, Chandiwana D, Gaur A, Lanoue B, Rodriguez-Lorenc K, Bardia A. Harbeck N, et al. Among authors: lanoue b. Ther Adv Med Oncol. 2020 Jul 26;12:1758835920943065. doi: 10.1177/1758835920943065. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32782490 Free PMC article.
Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2- advanced breast cancer.
Tripathy D, Curteis T, Hurvitz S, Yardley D, Franke F, Babu KG, Wheatley-Price P, Im YH, Pencheva R, Eddowes LA, Dionne PA, Chandiwana D, Pathak P, Lanoue B, Harbeck N. Tripathy D, et al. Among authors: lanoue b. Ther Adv Med Oncol. 2022 Feb 28;14:17588359221081203. doi: 10.1177/17588359221081203. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35251320 Free PMC article.